Article Details

Cantor Fitzgerald Reaffirms “Buy” Rating for Rigel Pharmaceuticals (NASDAQ:RIGL)

Retrieved on: 2019-03-20 07:48:45

Tags for this article:

Click the tags to see associated articles and topics

Cantor Fitzgerald Reaffirms “Buy” Rating for Rigel Pharmaceuticals (NASDAQ:RIGL). View article details on hiswai:

Excerpt

<div><b>Sofinnova Ventures</b> Inc grew its holdings in Rigel Pharmaceuticals by 43.5% during the 3rd quarter. <b>Sofinnova Ventures</b> Inc now owns 3,260,931 ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up